DelMar Pharmaceuticals Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

SAN DIEGO, May 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ( " DelMar " or the " Company " ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today it has enrolled 22...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials